GlassScriptPhysician profile
Vijay K Chadha
NPI 1629180898
$6,734.97
in general payments reported to CMS, 2019-2025
27 companies · $646 in 2025
The $646 reported for 2025 was more than what 83% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $1,103 · 2021: $1,391 · 2022: $928 · 2023: $1,051 · 2024: $930 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,481 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,480.85 |
| Education | $145.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,401.84 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $940.95 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $623.79 | 2019-2025 | Synthroid, Ubrelvy, Qulipta |
| Lilly USA, LLC | $556.19 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Pfizer INC. | $524.45 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $399.42 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.68 | 2019-2024 | Jardiance, Tradjenta |
| Amarin Pharma, INC. | $230.46 | 2019-2021 | |
| Astellas Pharma US INC | $210.50 | 2023-2024 | Veozah |
| Exact Sciences Corporation | $186.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $156.27 | 2019-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $145.53 | 2022-2024 | |
| Abbott Laboratories | $138.44 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $125.81 | 2020-2021 | |
| Glaxosmithkline, LLC. | $114.19 | 2020-2024 | Arexvy, Trelegy Ellipta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $112.81 | 2020-2024 | Nexletol |
| Genentech USA, INC. | $89.75 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $76.71 | 2019-2023 | |
| Allergan, INC. | $75.58 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $50.43 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $47.76 | 2024-2025 | Purified Cortrophin Gel, Sovuna |
| Ibsa Pharma INC. | $43.50 | 2020-2021 | |
| Dexcom, INC. | $25.05 | 2024 | Dexcom G6 Transmitter |
| Irhythm Technologies, INC. | $21.58 | 2022 | |
| Horizon Therapeutics Plc | $18.76 | 2021 | |
| Amneal Pharmaceuticals LLC | $16.74 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Chadha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.